Gene Therapy Shows Promise for Children With LAD-I

Leukocyte Adhesion Deficiency-I (LAD-I) is a rare genetic disease that leaves children vulnerable to severe infections.

Patients with LAD-I cannot mount normal immune responses against bacteria and fungi. As a result, they often experience recurring infections, frequent hospitalizations, and life-threatening complications.

Current treatment options are limited, creating an urgent need for new therapies.

Now, a CIRM-funded clinical trial is producing encouraging early results.

A Gene Therapy for a Life-Threatening Immune Disorder

LAD-I occurs when mutations reduce production of a protein called CD18.

CD18 helps immune cells move to infection sites and fight invading pathogens.

Without enough CD18, the immune system cannot function effectively.

Rocket Pharmaceuticals is testing a gene therapy called RP-L201 to address the disease’s underlying cause.

The therapy uses a patient’s own blood stem cells.

Researchers collect those cells and insert a healthy copy of the defective gene. They then return the corrected stem cells to the patient.

The goal is to restore production of functional immune cells and help the body fight infections.

Previous research suggests that even modest increases in CD18 levels can dramatically improve outcomes. Patients who reach CD18 expression levels between 4% and 10% often survive into adulthood.

Early Trial Results Show Encouraging Progress

Rocket Pharmaceuticals recently reported results from four patients treated in the ongoing clinical trial.

The patients ranged in age from seven months to nine years at enrollment.

Researchers followed the patients for periods ranging from three to 18 months after treatment.

The results have been encouraging.

The therapy was well tolerated in all four patients. Researchers reported no major safety concerns related to treatment or infusion.

They also observed substantial increases in CD18 expression:

  • A nine-year-old patient achieved approximately 40% CD18 expression 18 months after treatment.
  • A three-year-old patient achieved approximately 28% CD18 expression after nine months.
  • A seven-month-old patient achieved approximately 70% CD18 expression after three months.
  • A two-year-old patient achieved approximately 51% CD18 expression after three months.

These levels far exceed the threshold historically associated with long-term survival.

Researchers also reported meaningful clinical improvements.

The oldest patient experienced complete resolution of skin lesions, and no new lesions developed during 18 months of follow-up.

Restoring the Immune System With Corrected Stem Cells

The findings suggest that RP-L201 may help address the root cause of LAD-I rather than simply treating symptoms.

By correcting a patient’s own blood stem cells, the therapy aims to create a lasting source of healthy immune cells.

If successful, the approach could reduce infections, decrease hospitalizations, and improve long-term survival.

“Today’s positive updates on our LAD-I program add to the growing body of encouraging evidence that RP-L201 may provide durable clinical benefit for patients with severe LAD-I who face recurrent, life-threatening infections from birth,” said Dr. Jonathan Schwartz, Chief Medical Officer and Senior Vice President of Rocket Pharmaceuticals.

Looking Ahead

The study remains ongoing, and researchers must continue monitoring patients to evaluate long-term safety and durability.

However, these early results offer hope for families affected by a devastating disease with few treatment options.

By targeting the underlying genetic defect, RP-L201 could restore immune function and transform outcomes for children born with LAD-I.

As the trial continues, researchers will gather additional evidence to determine whether this gene therapy can deliver lasting protection against the infections that define the disease.

One thought on “Gene Therapy Shows Promise for Children With LAD-I”

  1. Gene therapy is a treatment for any disorder or pathophysiologic state bases upon the transfer of a normal copy of a single defective gene would revert the disease pathogenesis or even prevent the development of disease. The genetic intervention tool is highly recommended to the patients with inherited metabolic genetic disorders, when protein based replacement strategies have proved therapeutically suboptimal. However, evidence proved that introducing of foreign DNA into cell can trigger transformation event into developing of neoplastic and cancer cell. Thus, altering the genetic organization and structure of cell are potential cancer causing factors. Both factors produce greater impacts on regulation and functional of nucleus cell. The alterations of nucleus function may elicit the process of mutation in genetic level of cell. Therefore, long-term follow up to the patients with gene therapy is recommended to avoid the patients from developing unexpected deteriorate condition in future.

    Gene therapy requires gene transfer vectors to deliver the therapeutic gene to the relevant target cell. Different vectors have different characteristics of DNA-carrying capacity, targeted cell types, duration and defined levels of expression. Humans in different stages of development have different requirement for growth hormones and factors. However, the levels of therapeutic gene expression is consistantly controlled by insertion promoter of viral vector. Those patients may eventually experience various levels of clinical deleterious outcome after several years of recovery.

Leave a Reply